Tonix Pharmaceuticals stock halted ahead of FDA approval news
BOULDER, CO - Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a micro-cap healthcare company with a market value of $4.95 million and 17.43% revenue growth in the last twelve months, announced Wednesday the launch of its hypochlorous acid-based diaper rash product for infants and children in major U.S. retail outlets.
The antimicrobial hydrogel is now available in 3,600 Walmart stores, on Amazon.com, and in several large grocery chains, according to the company’s press release. The product is being distributed through Sonoma’s U.S.-based partner. According to InvestingPro analysis, while the company maintains strong liquidity with a current ratio of 2.7, it faces profitability challenges with negative earnings in recent quarters.
"We are excited to see our strategy of expanding into the over-the-counter space begin to take hold with our first U.S. product targeted to consumers launched into large scale retail channels," said Amy Trombly, CEO of Sonoma Pharmaceuticals.
The diaper rash product utilizes Sonoma’s patented Microcyn technology, which is based on stabilized hypochlorous acid (HOCl). The company develops HOCl products for various applications including wound care, eye, oral and nasal care, dermatological conditions, and animal health care.
Sonoma Pharmaceuticals, headquartered in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico, markets its products in 55 countries worldwide.
The company’s stock trades on the Nasdaq under the ticker symbol SNOA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.